Abstract：【Objective】 To investigate the efficacy of apatinib mesylate in the treatment of advanced ovarian cancer. 【Methods】A total of 94 patients with advanced ovarian cancer were treated with chemotherapy based on paclitaxel and carboplatin (control group),and 47 patients were treated with apatinib mesylate (observation group). The short-term efficacy,3-year survival rate and survival time of the two groups were compared. The changes of serum human epididymal protein 4 (HE4),carbohydrate antigen 125 (CA125) and kallikrein 10 (hK10) levels before and after chemotherapy were compared. 【Results】After chemotherapy,the total effective rate in the observation group was 66.67% (30/45),higher than 45.65% (21/46) in the control group,and the difference was statistically significant (P<0.05). Before chemotherapy,there was no significant difference in serum CA125,HE4 and hK10 levels between the two groups (P>0.05); After chemotherapy,the levels of serum CA125,HE4 and hK10 in the observation group were lower than those in the control group,and the difference was statistically significant (P<0.05). The 3-year cumulative survival rate in the observation group was 44.44% (20/45),which was higher than 32.61% (15/46) in the control group (P<0.05); The overall survival time of the observation group was 35.00 months,which was longer than that of the control group (28.00 months) (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】On the basis of routine regimen,the addition of apatinib mesylate can reduce the serum levels of CA125,HE4 and hK10 in patients with advanced ovarian cancer,and improve the short-term chemotherapy effect and long-term prognosis.
董飞天, 李瑞宁. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清HE4、hK10、CA125水平的影响[J]. 医学临床研究, 2022, 39(7): 1054-1057.
DONG Fei-tian, LI Rui-ning. Effect of Apatinib Mesylate on Ovarian Cancer and Serum Levels of HE4,hK10 and CA125. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1054-1057.
[1] 耿海燕. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效评价及其对血清HE4、CA 125及CA 199的影响[J].中国临床实用医学,2017,8(2):73-74.
[2] 谢幸,孔北华,段涛. 妇产科学.第9版[M]. 北京:人民卫生出版社,2018:313-322.
[3] WU L U,HE K E,DING Q S,et al. Apatinib has anti-tumor effects and induces autophagy in colon cancer cells[J].Iranian J Basic Med Sci,2017,20(9):990-995.
[4] PENG Y,SUN M L,WANG Y,et al. Effective apatinib treatment of pleomorphic liposarcoma: A case report[J].Medicine,2017,96(33):7771.
[5] 张文钰,车向明,韩超. 大剂量羟考酮治疗晚期复发性卵巢癌患者神经病理性疼痛的疗效及生存的影响[J].癌症进展,2019,17(11): 1302-1305.
[6] FENG S Q,WANG H,WANG Y,et al. Apatinib induces 3 ydroxybutyric acid production in the liver of mice by PPARα activation to aid its anti-tumor effect[J].Cancer Sci,2019,110(10):22-27.
[7] CHENG X,FENG H RM,WU H X,et al. Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer[J].Cancer Lett,2018,431(12):98-104.
[8] PENG Q X,HAN Y W,ZHANG Y L,et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma[J].Oncotarget,2017,8(32):52813-52822.
[9] 律慧敏,张梦玮,牛李敏,等. 甲磺酸阿帕替尼单药治疗多药耐药晚期乳腺癌临床观察[J].中华医学杂志,2018,98(16):1246-1249.
[10] LIANG L J. Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report[J].Medicine,2017,96(47):8725.
[11] 宋东,杨晓玲,冯慧晶,等. 低剂量阿帕替尼治疗晚期恶性肿瘤的安全性及有效性分析[J].肿瘤研究与临床,2019,31(7):469-473.
[12] SHI C Y,FENG Y,ZHANG L C,et al. Effective treatment of apatinib in desmoplastic small round cell tumor: A case report and literature review[J].BMC Cancer,2018,18(1):338.
2022, Vol. 39 
